Supernus (SUPN) Q4 2025 earnings review
Top-Line Triumph Obscures Growing Profitability Squeeze
Supernus delivered a record Q4, with total revenue accelerating to 21% YoY growth ($211.6M). The successful Sage Therapeutics acquisition is paying immediate dividends, with ZURZUVAE collaboration revenue adding $32.8M. However, the organic growth engine showed serious signs of fatigue. Qelbree, the company's flagship ADHD drug, saw net sales growth decelerate sharply to just 9% due to gross-to-net pricing pressures. Worse, the surge in revenue is not reaching the bottom line. FY26 guidance projects robust top-line growth of ~19%, yet Adjusted Operating Earnings are expected to slightly decline, signaling that aggressive SG&A and R&D investments are completely absorbing the new gross profit.
🐂 Bull Case
The Sage acquisition has been swiftly integrated. ZURZUVAE contributed $53M in just five months of 2025, and Biogen-reported US sales skyrocketed 187% YoY in Q4. It has successfully replaced the revenue hole left by legacy LOEs.
After pausing new patient initiations in Q3 due to supplier constraints, Supernus resumed initiations in Q1 2026. The Q4 sales resilience ($8.9M) and strong FY26 guidance ($45M-$70M) confirm that underlying demand remains robust.
🐻 Bear Case
Despite Q4 prescriptions growing 18%, Qelbree net sales grew only 9%. Management cited an 'annual gross-to-net deduction.' If payer rebate pressures are structural, the primary organic growth driver will fail to meet long-term expectations.
Supernus is guiding for a ~$136M top-line increase in FY26, yet expects Adjusted Operating Earnings to drop slightly at the midpoint. Commercial investments are consuming all incremental margin.
⚖️ Verdict: ⚪
Neutral. Management has successfully bridged the patent cliff via M&A, securing a strong top-line trajectory. However, structural pricing pressures on Qelbree and an uninspiring profit outlook for 2026 cap the upside until the company proves it can generate operational leverage.
Key Themes
Qelbree Growth Wall
Qelbree has hit a noticeable deceleration phase. Net sales growth went from 43% YoY in 25Q1, to 31% in Q2 and Q3, and suddenly plummeted to 9% in Q4. The divergence between volume growth (Rx +18%) and net sales growth (+9%) highlights significant gross-to-net (GTN) pricing erosion. This breaks the previous narrative of Qelbree as a highly profitable growth anchor.
ZURZUVAE Validates the Sage Acquisition
ZURZUVAE is accelerating rapidly. The Q4 collaboration revenue of $32.8M (representing 50% of net revenues from partner Biogen) marks a 62% sequential increase from Q3's $20.2M (which represented a partial quarter). With total 2025 prescriptions up over 150%, this asset is providing a massive, high-margin tailwind that is offsetting legacy product decay.
ONAPGO Back Online
Management successfully navigated the supply chain bottleneck that derailed ONAPGO in Q3. With new patient initiations resuming in Q1 2026 and a second supplier slated for 2027, the product is back on track. Q4 sales of $8.9M reflect strong retention of existing patients during the pause.
Margin Compression and High Spend
The transition to new products is proving expensive. Combined R&D and SG&A expenses surged 38% in FY25 to $591.8M (driven largely by Sage-related additions) and are guided even higher to $620-$650M in FY26. Consequently, Adjusted Operating Earnings are decelerating, signaling that the current commercial footprint requires heavy funding to sustain market share.
Legacy Products in Freefall
Trokendi XR and Oxtellar XR are eroding faster than previously anticipated. Combined Q4 sales were just $15.2M (down ~45% YoY). FY26 guidance projects they will shrink to $40-$50M annually, effectively removing them as meaningful contributors to cash flow.
Other KPIs
A reversing trend compared to Q4 2024's $21.4M operating profit. The shift is driven by $89.5M in FY25 intangible asset amortization and heightened SG&A run-rates following the Sage integration. The gap between GAAP losses and Non-GAAP profits is widening.
Down from $453.6M at the end of 2024. The drop strictly reflects the capital deployment used to acquire Sage Therapeutics. However, the balance remains exceptionally healthy, providing ample runway for ongoing commercialization without the need to tap debt markets.
Guidance
Accelerating. The $855M midpoint represents an impressive 19% YoY growth from FY25 ($719M). This top-line momentum is driven primarily by the full-year inclusion of ZURZUVAE and the resumption of ONAPGO growth.
Accelerating. Implies a massive jump from FY25's $17.3M. This guidance demonstrates high management confidence that the Q3 supply pause did not permanently damage physician trust or patient demand pipelines.
Stable to slightly Decelerating. The $155M midpoint implies a 2% decline from FY25 ($158.7M), despite $136M in anticipated new revenue. This signals severe negative operating leverage expected in the coming year.
Key Questions
Qelbree Gross-to-Net Dynamics
You cited an 'annual gross-to-net deduction' as the primary offset to Qelbree's 18% prescription growth in Q4. Is this a one-time true-up, or does it represent a structural change in payer rebate requirements heading into 2026?
Profitability Disconnect
Guidance projects ~19% top-line growth in FY26, yet Adjusted Operating Earnings are guided flat-to-down. Where exactly is the incremental gross profit from ZURZUVAE and ONAPGO being spent, and when should investors expect operating leverage to return?
ONAPGO Supply Chain Confidence
Given the target of up to $70M in ONAPGO sales for 2026, are you fully confident the current sole supplier can meet this volume, or will supply remain a tightly managed bottleneck until the second supplier comes online in 2027?